Search Results for: masayo takahashi

Stem Cell TGIF on Friday the 13th: My Reactions to the Big Recent Stories

On May 13, 2011 I published a post entitled “Friday the 13th for iPS cells”. That day was indeed Friday the 13th and there were some reports in Nature of concerns about iPS cells in terms of immunogenicity and this had followed on the heels of reports on significant genomic and epigenomic warts in iPS …

Stem Cell TGIF on Friday the 13th: My Reactions to the Big Recent Stories Read More »

Japan Aiming For a Commanding Position on New Stem Cells

Masayo-Takahashi-ISSCR-300x239

Stem cell technology is poised to wow the world with biomedical advances in the coming decades and Japan wants to lead the way. They want to forge ahead particularly with applications that focus on a relatively new kind of stem cells called induced pluripotent stem cells or iPS cells. Japanese researcher, Shinya Yamanaka, first reported production …

Japan Aiming For a Commanding Position on New Stem Cells Read More »

FDA & Japanese Health Ministry (厚生労働省) To Develop iPS cell clinical rules

FDA3-300x2581

In a rare sign of stem cell international regulatory unity, the Japanese Health Ministry (厚生労働省) and the US FDA have agreed to develop a joint, unified regulatory framework for clinical studies of human iPS cells for use in treating retinal diseases. Presumably the rules would also guide clinical use of iPS cells to treat other …

FDA & Japanese Health Ministry (厚生労働省) To Develop iPS cell clinical rules Read More »

Asahi Shimbun Editorial: iPS Cells Rushed For Economic Reasons

In a shocker, Japan’s 2nd largest newspaper, Asahi Shimbun, published an editorial yesterday  saying that iPS cells are being pushed too fast to the clinic for economic reasons. The piece was bluntly entitled “Too much of a rush for clinical trials with iPS cells”. Asahi Shimbun, with a circulation of 10 million, is taking a bold …

Asahi Shimbun Editorial: iPS Cells Rushed For Economic Reasons Read More »

As iPS cell studies in humans approach, accessible relevant pre-clinical data remains minimal

IPS cells, induced pluripotent stem cells, Knoepfler lab, stained for TRA-1-60, an ES cell marker., where do stem cells come from?

When are iPS cell-based therapies ready to be tested in actual people? It’s the million or perhaps even billion dollar question of today in the stem cell field. I realize that perhaps it is also a dangerous question, politically-speaking, for me to ask in a public forum, but patient lives as well as potentially the …

As iPS cell studies in humans approach, accessible relevant pre-clinical data remains minimal Read More »

Interviews

I’ve been fortunate to interview some of the greats in the stem cell field for this blog and host debates between key players. Please note that just because I have interviewed folks does not mean I agree with them or that they agree with me. The point is to establish dialogue on key issues. As …

Interviews Read More »

iPS cell pre-clinical data should be published before starting first human clinical trials

human-IPS-cells-made-in-Knoeplfer-lab-stained-for-TRA-160

It is always exciting when a biomedical technology as revolutionary as iPS cells is on the cusp of being used in patients for the first time. In the last few days stories have reported about how a proposed clinical trial based on iPS cells has completed several regulatory steps and is closer to starting. This …

iPS cell pre-clinical data should be published before starting first human clinical trials Read More »

Are iPS cells being rushed to the clinic or has their time come?

The iPS cell field has run fast and furious over the past 6 years reaching a big milestone surprisingly quickly on Monday with Shinya Yamanaka winning the Nobel Prize. But is  the field going too fast? In August I argued that iPS cells are not quite ready for primetime (i.e. clinical trial studies). Now in …

Are iPS cells being rushed to the clinic or has their time come? Read More »